{"schema_version":"secwatch.filing_event.v1","accession":"0001372514-23-000101","form_type":"8-K","ticker":"KPRX","cik":"0001372514","company_name":"KIORA PHARMACEUTICALS INC","filed_at":"2023-06-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.601632+00:00","generated_at":"2026-06-13T23:56:27.525108+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Kiora Pharmaceuticals eliminates $4.75M in milestone payments to Sentrx; grants animal health license for royalty","bullets":["Amendment cancels up to $4.75M in near-term milestones Kiora owed Sentrx under 2018 license.","Kiora grants Sentrx exclusive license to KIO-201 patents for veterinary use; Kiora receives low single-digit royalty on net sales.","Kiora retains optionality to source alternative manufacturing partners for KIO-201.","KIO-201 is a modified hyaluronic acid for persistent corneal epithelial defects, a rare disease."],"urls":{"canonical":"https://secwatch.observer/filing/0001372514-23-000101","json":"https://secwatch.observer/filing/0001372514-23-000101.json","markdown":"https://secwatch.observer/filing/0001372514-23-000101.md","text":"https://secwatch.observer/filing/0001372514-23-000101.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1372514/000137251423000101/0001372514-23-000101-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1372514/000137251423000101/kprx-20230612.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T23:56:27.525108+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}